Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia

NCT02602314 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

450

Enrollment

OTHER

Sponsor class

Conditions

Chronyc Myeloid Leukemia

Interventions

DRUG: Imatinib
DRUG: Nilotinib

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto